Operational excellence - The future of biopharmaceutical manufacturing

Innovations in Pharmaceutical Technology

Volumn , Issue 26, 2008, Pages 57-60

  Jagschies, Günter ^a  

^a GE Healthcare Life Sciences   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RESIN;

ANTIBODY PRODUCTION; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; CHROMATOGRAPHY; DISPOSABLE EQUIPMENT; DOWNSTREAM PROCESSING; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; PROCESS CONTROL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; PRODUCT DEVELOPMENT; PRODUCTIVITY;

EID: 55049129231     PISSN: 14717204     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (10)

1. Bornsztejn V and Ebbens M, Leaning the way in Bioprocess, www1.gelifesciences.com
2. http://en.wikipedia.org/wiki/Sakichi_Toyoda
3. Kelley B, Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations, Biotechnol Prog, 23, pp995-1,008, 2007
4. Jagschies Q, Quo vadis? - Where are we heading biopharma?, BioPharm International, in print
5. Biotechnology Medicines Survey, 2004, http://www.phrma.org/
6. Biotechnology Medicines Survey, 2006, http://www.phrma.org/
7. Driscoll C, A Lean Version of Lean, www.contractpharma.com, June 2006
8. Process Chromatography Handbook, 2nd edition, eds Hagel L, Jagschies G and Sofer G, Elsevier, 2007
9. Vunnum S, Anion Exchange Purification of MAbs: Weak Partitioning Chromatography, presented at ACS, BlOT Division, San Francisco, September 2006
10. Johansson HJ, Current and future advances in development of downstream processes for purification of monoclonal antibodies, presented at IBC Bioprocess International Conference, San Francisco, November 2006